A Single-Dose, Single-Blind, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BIIB019, Daclizumab High Yield Process (DAC HYP), in Japanese and Caucasian Adult Healthy Volunteers

Trial Profile

A Single-Dose, Single-Blind, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BIIB019, Daclizumab High Yield Process (DAC HYP), in Japanese and Caucasian Adult Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2015

At a glance

  • Drugs Daclizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacokinetics
  • Sponsors Biogen Idec
  • Most Recent Events

    • 01 May 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Feb 2014 Planned End Date changed from 1 Feb 2014 to 1 Mar 2014 as reported by ClinicalTrials.gov record.
    • 28 Feb 2014 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top